| Bioactivity | TP0586532 is a non-hydroxamate LpxC inhibitor (IC50=0.101 μM). TP0586532 as a compound with a low cardiovascular risk that is effective against K. pneumoniae, including resistant strains[1]. | ||||||||||||
| Target | IC50: 0.101 μM (non-hydroxamate LpxC) | ||||||||||||
| Invitro | TP0586532 as a compound with a low cardiovascular risk that is effective against K. pneumoniae, including resistant strains[1]. | ||||||||||||
| Name | TP0586532 | ||||||||||||
| CAS | 2427584-96-9 | ||||||||||||
| Formula | C26H28N4O4 | ||||||||||||
| Molar Mass | 460.52 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ushiyama F, et al. Lead optimization of 2-hydroxymethyl imidazoles as non-hydroxamate LpxC inhibitors: Discovery of TP0586532. Bioorg Med Chem. 2021;30:115964. |